Ann: Viralytics and Merck Collaborate in Lung and Bladder Cancer, page-8

Intravenous delivery. The real potential for Cavatak has always been intravenous delivery. Until this stage Cavatak has only been shown to work by direct injection into a lesion. While a big market, small in comparison to the markets of lung and bladder and probably many others.
Merck will have looked closely at the early stage Intravenous results and they must be impressive for Merck to join a combination trial.
Cavatak/Viralytics is no longer just a direct injection into melanoma product. It is a combination treatment for major cancers which is publicly recognised by a player as big as Merck.
It may take the Australian market a while to wake up to this but watch the VRACY price react in the US tonight.